RTW Investments Increases Stake in Tango Therapeutics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 30 2026
0mins
Source: NASDAQ.COM
Tango Therapeutics Inc's stock fell 6.93% as it crossed below the 20-day SMA amid broader market gains.
RTW Investments acquired 11,809,392 shares of Tango Therapeutics last quarter for approximately $164.37 million, reflecting strong confidence in the biotechnology sector. This acquisition increased RTW's stake to about 3%, indicating a strategic positioning in precision medicine. Additionally, Tango's lead candidate, vopimetostat, is showing promising early results in ongoing studies targeting specific cancers, with management optimistic about upcoming clinical data.
The significant investment from RTW Investments highlights the potential for Tango Therapeutics in advancing precision cancer therapies, despite the recent stock decline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TNGX
Wall Street analysts forecast TNGX stock price to fall
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 32.290
Low
12.00
Averages
13.67
High
15.00
Current: 32.290
Low
12.00
Averages
13.67
High
15.00
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Tango Therapeutics Successfully Prices Public Offering
- Upsized Offering: Tango Therapeutics priced its public offering of 18.17 million shares at $30.00 each, increasing the gross proceeds to approximately $600 million from the previously announced $500 million, reflecting strong market demand for its precision oncology products.
- Pre-Funded Warrants: The offering includes pre-funded warrants allowing the purchase of up to 1.833 million shares at $29.99 each, enhancing investor participation and interest in the offering.
- Underwriter Team: J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating strong market confidence and support for the company.
- Stock Price Movement: Tango's shares closed at $31.56 on Tuesday, up 2.04%, but dipped slightly to $31.14 in after-hours trading, reflecting a positive investor reaction to the offering news.
See More
Tango Therapeutics Prices Upsized $600M Public Offering
- Upsized Offering: Tango Therapeutics announced an upsized public offering of 18.17 million shares and 1.83 million pre-funded warrants, with expected gross proceeds of approximately $600 million, reflecting a $100 million increase from the initial target of $500 million, indicating strong market demand for its stock.
- Pricing Details: The common stock is priced at $30.00 per share, while the pre-funded warrants are priced at $29.999 each, which reflects the public offering price minus a $0.001 exercise price, showcasing the company's flexibility in financing.
- Underwriter Option: Tango has granted underwriters a 30-day option to purchase an additional 3 million shares at the public offering price, a strategy that could enhance its financing capabilities and attract more investors.
- Expected Closing Date: The offering is expected to close on or about June 11, 2026, subject to customary closing conditions, demonstrating the company's proactive approach in capital markets.
See More
Tango Therapeutics Prices $600 Million Underwritten Offering
- Offering Size: Tango Therapeutics announced the pricing of 18,166,667 shares of common stock at $30.00 each and pre-funded warrants for 1,833,395 shares, with expected gross proceeds of approximately $600 million, indicating strong market demand for its precision cancer medicines.
- Underwriter Selection: J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering, reflecting the company's credibility in capital markets and potentially laying the groundwork for future financing activities.
- Additional Share Option: Tango granted underwriters a 30-day option to purchase an additional 3,000,009 shares, a strategy that not only provides flexibility for further financing but may also enhance investor confidence in the company's growth prospects.
- Compliance and Transparency: The offering is made pursuant to an effective shelf registration statement filed with the SEC, ensuring compliance and transparency, which helps to bolster investor trust and the company's market image.
See More
Tango Therapeutics Prices $600 Million Underwritten Offering
- Offering Size: Tango Therapeutics announced an underwritten offering of 18,166,667 shares at $30 each and pre-funded warrants for 1,833,395 shares, with expected gross proceeds of approximately $600 million, reflecting strong market demand for its precision cancer medicines.
- Underwriter Selection: The involvement of J.P. Morgan, Leerink Partners, Cantor, and Stifel as joint bookrunning managers indicates significant confidence from these reputable financial institutions, potentially increasing investor interest in Tango.
- Additional Share Option: Tango has granted underwriters a 30-day option to purchase an additional 3,000,009 shares, a strategy that not only provides the company with added financial flexibility but also allows for scaling up the offering in response to strong market demand.
- Compliance and Transparency: The offering is made under an effective shelf registration statement filed with the SEC, ensuring compliance and transparency, which enhances investor confidence in the company's future growth prospects.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Tango Therapeutics Launches $500M Underwritten Public Offering
- Offering Size: Tango Therapeutics has announced a public offering of $500 million in common stock, aimed at raising capital to support its research and operational activities.
- Additional Purchase Option: The company also intends to grant underwriters a 30-day option to purchase an additional $75 million in common stock, which could further enhance its fundraising capabilities.
- Stock Price Reaction: Following the announcement, TNGX's stock price fell by 2.74% to $30.12, reflecting market caution regarding the financing, which may impact investor confidence.
- Clinical Progress Context: Tango has recently reported promising clinical results for treating MTAP-deleted pancreatic cancer, and while this financing may affect short-term stock performance, the long-term research potential remains noteworthy.
See More
Tango Therapeutics Successfully Prices Public Offering
- Upsized Offering: Tango Therapeutics priced its public offering of 18.17 million shares at $30.00 each, increasing the gross proceeds to approximately $600 million from the previously announced $500 million, reflecting strong market demand for its precision oncology products.
- Pre-Funded Warrants: The offering includes pre-funded warrants allowing the purchase of up to 1.833 million shares at $29.99 each, enhancing investor participation and interest in the offering.
- Underwriter Team: J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint book-running managers for the offering, indicating strong market confidence and support for the company.
- Stock Price Movement: Tango's shares closed at $31.56 on Tuesday, up 2.04%, but dipped slightly to $31.14 in after-hours trading, reflecting a positive investor reaction to the offering news.
See More
Tango Therapeutics Prices Upsized $600M Public Offering
- Upsized Offering: Tango Therapeutics announced an upsized public offering of 18.17 million shares and 1.83 million pre-funded warrants, with expected gross proceeds of approximately $600 million, reflecting a $100 million increase from the initial target of $500 million, indicating strong market demand for its stock.
- Pricing Details: The common stock is priced at $30.00 per share, while the pre-funded warrants are priced at $29.999 each, which reflects the public offering price minus a $0.001 exercise price, showcasing the company's flexibility in financing.
- Underwriter Option: Tango has granted underwriters a 30-day option to purchase an additional 3 million shares at the public offering price, a strategy that could enhance its financing capabilities and attract more investors.
- Expected Closing Date: The offering is expected to close on or about June 11, 2026, subject to customary closing conditions, demonstrating the company's proactive approach in capital markets.
See More
Tango Therapeutics Prices $600 Million Underwritten Offering
- Offering Size: Tango Therapeutics announced the pricing of 18,166,667 shares of common stock at $30.00 each and pre-funded warrants for 1,833,395 shares, with expected gross proceeds of approximately $600 million, indicating strong market demand for its precision cancer medicines.
- Underwriter Selection: J.P. Morgan, Leerink Partners, Cantor, and Stifel are acting as joint bookrunning managers for the offering, reflecting the company's credibility in capital markets and potentially laying the groundwork for future financing activities.
- Additional Share Option: Tango granted underwriters a 30-day option to purchase an additional 3,000,009 shares, a strategy that not only provides flexibility for further financing but may also enhance investor confidence in the company's growth prospects.
- Compliance and Transparency: The offering is made pursuant to an effective shelf registration statement filed with the SEC, ensuring compliance and transparency, which helps to bolster investor trust and the company's market image.
See More
Tango Therapeutics Prices $600 Million Underwritten Offering
- Offering Size: Tango Therapeutics announced an underwritten offering of 18,166,667 shares at $30 each and pre-funded warrants for 1,833,395 shares, with expected gross proceeds of approximately $600 million, reflecting strong market demand for its precision cancer medicines.
- Underwriter Selection: The involvement of J.P. Morgan, Leerink Partners, Cantor, and Stifel as joint bookrunning managers indicates significant confidence from these reputable financial institutions, potentially increasing investor interest in Tango.
- Additional Share Option: Tango has granted underwriters a 30-day option to purchase an additional 3,000,009 shares, a strategy that not only provides the company with added financial flexibility but also allows for scaling up the offering in response to strong market demand.
- Compliance and Transparency: The offering is made under an effective shelf registration statement filed with the SEC, ensuring compliance and transparency, which enhances investor confidence in the company's future growth prospects.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
Tango Therapeutics Launches $500M Underwritten Public Offering
- Offering Size: Tango Therapeutics has announced a public offering of $500 million in common stock, aimed at raising capital to support its research and operational activities.
- Additional Purchase Option: The company also intends to grant underwriters a 30-day option to purchase an additional $75 million in common stock, which could further enhance its fundraising capabilities.
- Stock Price Reaction: Following the announcement, TNGX's stock price fell by 2.74% to $30.12, reflecting market caution regarding the financing, which may impact investor confidence.
- Clinical Progress Context: Tango has recently reported promising clinical results for treating MTAP-deleted pancreatic cancer, and while this financing may affect short-term stock performance, the long-term research potential remains noteworthy.
See More
